Research guide

Selank: Tuftsin-Analogue Research Guide

Selank is built the same way Semax is: take a short naturally occurring peptide, attach a proline-glycine-proline tail so enzymes cannot destroy it as fast, and study what the stabilised version does. Different parent peptide, same engineering idea — which is why the two compounds are almost always read together. The material supplied here is not approved by any regulatory authority. This guide sets out what the published research has examined, with an identifier for every study named.

Identifiers

Common name: Selank
Compound class: Synthetic analogue of tuftsin
Parent peptide: Tuftsin, a short naturally occurring peptide
Structural modification: Proline-glycine-proline tail — the same extension used on Semax
Regulatory status: The material supplied here is not approved by any regulatory authority
Supplied by Prime Peptides UAE as: 10mg vial — Selank product page

What Selank is

Tuftsin is a short peptide the body produces. On its own it is, like most very short peptides, quickly broken down. Selank is a synthetic analogue of it carrying a proline-glycine-proline extension — the identical stabilising strategy applied to Semax’s ACTH fragment.

That shared design is not a coincidence and it is the single most useful fact for reading this literature. Both compounds come out of the same research programme and the same structural idea: a naturally occurring short peptide is interesting but too fragile to study easily, so attach a Pro-Gly-Pro tail and study the version that survives. A great deal of the published work on this family is structured as a comparison between the two, which is why sources on one frequently discuss the other, and why a reader looking into Selank should expect to meet Semax on the way.

Terms of this kind are collected in the research peptide terminology glossary. The companion compound is covered in the Semax research guide.

What the published literature has examined

The same qualifier that applies to Semax applies here: much of the primary literature on this compound is Russian-language and published in journals with weaker international indexing.

The retrievable, independently checkable record is narrower than the volume of writing about the compound suggests. This guide cites what a reader can actually go and read. Magnitudes are deliberately omitted throughout.

Gene expression in rat frontal cortex, 2016

Volkova and colleagues, Frontiers in Pharmacology (PMID 26924987). Examined the expression of genes involved in neurotransmission in rat frontal cortex, reported statistically significant changes in gene expression, and proposed allosteric modulation of the GABAergic system as one possible molecular mechanism.

Two things about that framing are worth keeping straight. Allosteric modulation means acting at a site on a receptor other than the one the natural signalling molecule binds — changing how the receptor responds rather than switching it on directly. And proposed as one possible mechanism is the authors’ own hedge, not ours: a gene-expression study can support a hypothesis about a mechanism without establishing it, and this paper says so itself.

Enzyme activity, 2001

Zozulya and colleagues, Bulletin of Experimental Biology and Medicine (PMID 11550013). Examined the compound’s effect on enkephalin-degrading enzyme activity.

Regulatory status

The material supplied here is not approved by any regulatory authority. It is not a medicine, and it is not supplied as one.

A separately manufactured Selank product has been registered as a prescription medicine in the Russian Federation since 2009. That registration covers that product, in that jurisdiction, under that manufacturer’s application. It does not extend to material supplied under the same compound name by other parties, including the material supplied here, and it establishes nothing about that material’s identity, purity, origin or suitability. Those questions are answered by a third-party lab report, not by another company’s regulatory file.

Prime Peptides UAE supplies Selank as a research material only.

What this literature does not establish

Published research attaches to a compound. It does not attach to a vial.

Both cited studies are rat studies. Gene expression in rat frontal cortex and enzyme activity measured in a rodent system are exactly that.
A proposed mechanism is not an established one. The 2016 paper offers allosteric modulation of the GABAergic system as one possible molecular mechanism, in its own words. A page that upgrades that to a settled account is not reporting the source.
The retrievable English-language record is narrow. A summary that reads as comprehensive on this compound should be checked against what it can point at.
A published paper says nothing about a research material’s provenance — how to read a peptide COA.

How Prime Peptides UAE documents Selank

Currently being tested. No third-party lab report is published for this product. Prime Peptides UAE publishes reports where it holds them and states plainly where it does not.

The reports we do hold are published in full, with the issuing laboratory’s verification keys, on Testing and Quality. Format, strength, AED price and current document status for this item are on the Selank product page.

For research purposes only. Not for human consumption.

Prime Peptides UAE supplies this compound as a laboratory research material. Full regulatory information: Product and Regulatory Information.

Common questions

What is Selank?

A synthetic analogue of tuftsin, a short naturally occurring peptide, extended with a proline-glycine-proline tail — the same stabilising extension used on Semax.

Why are Selank and Semax always discussed together?

Because they are the same engineering idea applied to two different parent peptides: a short natural peptide plus a Pro-Gly-Pro tail to slow enzymatic breakdown. Much of the published work on this family is structured as a comparison between the two.

What form does Prime Peptides UAE supply Selank in?

A 10mg vial. Format, strength, AED price and current document status are on the Selank product page.

Is Selank approved by a regulator?

The material supplied here is not approved by any regulatory authority. A separately manufactured Selank product has been registered as a prescription medicine in the Russian Federation since 2009; that registration covers that product in that jurisdiction and does not extend to material supplied under the same compound name by other parties. Prime Peptides UAE supplies Selank as a research material only.

What has the published research examined?

Two retrievable primary sources are cited here: gene expression involved in neurotransmission in rat frontal cortex, with allosteric modulation of the GABAergic system proposed as one possible mechanism (Volkova et al., Frontiers in Pharmacology, 2016, PMID 26924987); and the compound’s effect on enkephalin-degrading enzyme activity (Zozulya et al., Bulletin of Experimental Biology and Medicine, 2001, PMID 11550013).

What does “allosteric modulation” mean?

Acting at a site on a receptor other than the one the natural signalling molecule binds — changing how the receptor responds rather than activating it directly. In the 2016 paper it is offered as one possible molecular mechanism, not as an established one.

Does Prime Peptides UAE publish a lab report for Selank?

Not yet. Currently being tested. No third-party lab report is published for this product. Prime Peptides UAE publishes reports where it holds them and states plainly where it does not — the ones we hold are on Testing and Quality.

References

Volkova A, et al. Frontiers in Pharmacology. 2016;7:31. Expression of genes involved in neurotransmission in rat frontal cortex; allosteric modulation of the GABAergic system proposed as one possible mechanism. PMID 26924987
Zozulya AA, et al. Bulletin of Experimental Biology and Medicine. 2001. Effect on enkephalin-degrading enzyme activity. PMID 11550013